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Extrahepatic cancers of the biliary system are typically asymptomatic until after
metastasis, which contributes to their poor prognosis. Here we examined intrahepatic
cholangiocarcinomas (n = 8), carcinomas of perihilar bile ducts (n = 7), carcinomas of the
gallbladder (n = 11) and hepatic metastasis from carcinomas of the gallbladder (n = 4) for
the expression of the extracellular matrix glycoproteins tenascin-C and tenascin-W. Anti-
tenascin-C and anti-tenascin-W immunoreactivity was found in all biliary tract tumors
examined. Unlike tenascin-C, tenascin-W was not detected in normal hepatobiliary tissue.
Tenascin-W was also expressed by the cholangiocarcinoma-derived cell line Huh-28.
However, co-culture of Huh-28 cells with immortalized bone marrow-derived stromal cells
was necessary for the formation and organization of tenascin-W fibrils in vitro. Our results
indicate that tenascin-W may be a novel marker of hepatobiliary tumor stroma, and its
absence from many normal tissues suggests that it may be a potential target
for biotherapies.
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Cancers originating in the epithelia of the biliary system are typically categorized as intrahepatic
cholangiocarcinoma (ICC), carcinoma of perihilar bile ducts (CPHBD) or carcinoma of the
gallbladder (CGB). While some early intrahepatic biliary system tumors have the potential to be
treated effectively by radiotherapy, chemotherapy, local resection or liver transplantation, cancers of
the extrahepatic biliary system have a particularly poor prognosis and limited options for therapy
(1). In CGB the best outcomes require early diagnosis and resection, but extrahepatic lesions
typically have asymptomatic development and most patients have metastatic disease by the time of
surgery (2). The mean survival rate following CGB diagnosis is 6 months, and the 5-year survival
rate is only 5% (3). CGB is more common in women than in men (4, 5) and while world-wide it is aorg February 2021 | Volume 11 | Article 6301391
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9). Some of these variations are likely related to regional rates of
cholelithiasis, as 74–92% of patients with CGB have
gallstones (10).
Tenascins are a family of extracellular matrix glycoproteins
that share a common domain architecture (11). The best studied
tenascin is the hexabrachion tenascin-C, which is required for
normal embryonic development and reappears in the stroma of
solid tumors (12, 13). Tenascin-C is abundant in the extracellular
matrix of cancers of the breast, colon, pancreas, prostate, uterus,
lung, skin, and brain, to name a few (14–16). In vitro, tenascin-C
promotes the proliferation and migration of many tumor-
derived cell lines (17) and there are reduced metastases in
tenascin-C knockout mice and in mice lacking factors that
promote the expression of tenascin-C (16). Tenascin-C may
also play a role in creating an immune suppressive tumor
stroma, thus contributing to tumor growth and metastasis (18).
Tenascin-C has been proposed as a marker, immunotherapy
target and indicator of prognosis in many kinds of cancer (16),
but its use has been limited by its presence, albeit at lower levels,
in many normal adult tissues (19).
Much less is known about tenascin-W, which is also known as
tenascin-N (20, 21). It is particularly abundant in the embryo,
especially at sites of osteogenesis (22). In the adult, it is found in
certain stem cell niches together with tenascin-C (23) but except
for the kidney and spleen its expression elsewhere in the adult is
sparse (24, 25). Like tenascin-C, tenascin-W can promote cell
migration in vitro, but it typically has little or no effect on cell
proliferation (21). Tenascin-W is also found in the stroma of
certain solid tumors. This was first reported in murine breast
carcinomas (26) and later in human breast and colon cancer (27,
28), and glioblastomas (29). Studies with normal human tissue
samples suggest that the expression of tenascin-W may be more
restricted in the adult than tenascin-C and may therefore be a
better marker of tumor stroma and a more appropriate target for
biotherapies (19).
Here we used immunohistochemistry to study the expression
of tenascin-C and tenascin-W in the stroma of ICC, CPHBD and
CGB, and we characterized biliary tract cancer-derived cell lines
for tenascin-W expression. We also studied the expression of
tenascin-W in a wide array of normal human tissues. Our goals
were to determine if tenascin-W represents a novel candidate for
use as a biliary tract cancer stromal marker and if tenascin-W is a
potential target for adjuvant therapy to fight cancers of the
biliary system.MATERIAL AND METHODS
Cases
This study was approved by the Mongi Slim University Hospital
(MSUH) Committee on Medical Ethics (La Marsa, Tunisia) and
the Ethikkommission Nordwest- und Zentralschweiz
(Switzerland). All methods were performed according to these
approved guidelines and regulations and are consistent with the
editorial and publication policies of this journal. Only MSUHFrontiers in Immunology | www.frontiersin.org 2patients who underwent biopsy or surgery for diagnosis or
treatment purposes were asked to participate by signing an
informed consent form. None of the patients received radio
and/or chemotherapy before biopsy or surgery. 17/18G
percutaneous needle biopsies or surgical resection were fixed in
Shandon™ Formal-Fixx™ 10% Neutral Buffered Formalin
(Thermo Fisher Scientific, Runcorn, UK) for 24 h and then
shipped in phosphate buffered saline (PBS) at 4°C to the
Friedrich Miescher Institute for Biomedical Research (Basel,
Switzerland) for processing. Upon reception, samples were
incubated overnight in PBS with 30% sucrose for
cryoprotection before being frozen at -80°C in Tissue-Tek
OCT Compound (Sakura Finetek USA, Torrance, CA, USA)
using acetone precooled with dry-ice. Histological diagnosis of
each biopsy/resection was performed by at least one of two
pathologists (A. L. and N. K.) according to the World Health
Organization classification of tumors (30). Tumors were staged
according to the Union for International Cancer Control 8th
TNM Classification of Malignant Tumors. Formalin-fixed and
paraffin-embedded tissue samples were obtained from the
Institute of Pathology of the University Hospital of Basel
(Basel, Switzerland) and FDA standard human adult normal
tissue frozen arrays were purchased from Biochain (Hayward,
CA, USA).
Immunohistochemistry
Both monoclonal mouse anti-human tenascin-C (B28-13) and anti-
human tenascin-W (56O) antibodies were generated and characterized
as described previously (27, 31). Immunohistochemistry experiments
were performed with a Ventana Discovery Ultra instrument (Roche
Diagnostics, Manheim, Germany). For fixed-frozen material, the
procedure RUO Discovery Universal was used. Sections were first
fixed with 4% formaldehyde for 12 min on-line and anti-tenascin-C
B28-13 (1:10000) or anti-tenascin-W 56O (1:30) were applied
manually and incubated for 1 h at 37°C. For anti-tenascin-W, a
blocker (Discovery antibody block, Roche Diagnostics) was applied.
To detect bound antibodies, a monoclonal rabbit-anti-mouse IgG
(ab133469, Abcam, Cambridge, UK) was used as a linker (0.6 mg/
ml) and applied for 20min. Antibody-antigen complexes were detected
with ImmPRESS anti-rabbit Ig (peroxidase) polymer reagent (MP-
7401, Vector Laboratories, Burlingame, CA, USA) applied manually
and incubated for 32 min. The ChromoMap DAB kit (Roche
Diagnostics) was used for detection. Finally, slides were
counterstained with Hematoxylin II and Bluing Reagent (Roche
Diagnostics) for 8 min.
For formalin-fixed, paraffin-embedded material, the
procedure RUO Discovery Universal was used with 40 min
CC1 pre-treatment. Anti-tenascin-C B28-13 (1:5000) or anti-
tenascin-W 56O (1:100) were applied manually and incubated
for 1 h at 37°C or 3 h at room temperature, respectively. For anti-
tenascin-C, secondary antibody (ImmPRESS reagent kit
peroxidase anti-mouse Ig MP-7402, Vector Laboratories) was
applied manually (200 μl) and incubated for 32 min at 37°C. For
anti-tenascin-W, a blocker (Dako antibody diluent with
background reducing component, S3022, Dako Agilent
Pathology Solutions, Santa Clara, CA, USA) was applied
together with the primary antibody. Detection of bound anti-February 2021 | Volume 11 | Article 630139
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anti-mouse HQ (Roche Diagnostics) and 24 min with anti-HQ
HRP (Roche Diagnostics). Finally, for both anti-tenascin-C and
anti-tenascin-W immunostainings, ChromoMap DAB kit
(Roche Diagnostics) was used for the detection and slides were
counterstained with Hematoxylin II and Bluing Reagent (Roche
Diagnostics) for 8 min.
For controls, sections were processed as above but without
primary antibodies. In addition, mouse IgG2A (Clone # 20102,
R&D systems) and mouse IgG1 (Clone # 11711, R&D systems)
were used as isotypic controls for anti-tenascin-C and anti-
tenascin-W, respectively. Control slides were unlabeled.
Cell Lines
Twenty human biliary tract cancer cell lines were collected from
different sources. Huh-28 (ICC), HuCCT1 (ICC), OZ (CPHBD),
NOZ (CGB) and OCUG-1 (CGB) cell lines were obtained from
the Japanese Collection of Research Bioresources Cell Bank.
TKKK (ICC), TFK-1 (CPHBD), TGBC1TKB (CGB), TGBC2
(CGB), TGBC14TKB (CGB), TGBC24TKB (CGB) and G-415
(CGB) cell lines were obtained from the RIKEN BioResource
Center. SNU-1079 (ICC), SNU-245 (CPHBD), SNU-1196
(CPHBD) and SNU-308 (CGB) cell lines were obtained from
the Korean Cell Line Bank. The Egi-1 (CPHBD) cell line was
obtained from the Leibniz Institute DSMZ - German Collection
of Microorganisms and Cell Cultures. All cell lines were cultured
as recommended by their respective cell banks. SK-ChA-1
(CPHBD), Mz-ChA-1 (CGB), Mz-ChA-2 (CGB) were obtained
from Prof. Alexander Knuth (University Hospital of Zürich,
Zürich, Switzerland) (32) and cultured in RPMI 1640 with 10
mM HEPES, 2 mM L-Glutamine, 1X MEM non-essential amino
acids (Thermo Fisher Scientific), 100 U/ml penicillin, 100 μg/ml
of streptomycin, and 10% fetal bovine serum (FBS). Human
BMSCs (196hT) immortalized with the hTERT/GFP system (33)
were cultured as described previously (34). The control cell line
293/hTNW that stably expresses human tenascin-W (27) was
cultured in DMEM with 0.25 μg/ml of G418, 1.5 μg/ml of
puromycin, and 10% FBS.
Cell Culture, Immunocytochemistry,
and siRNA Transfection
For the co-culture assay, Huh-28 and 196hT cell lines were
cultured in a-MEM plus 10% FBS, either alone or together at 1:1
ratio, with a total density of 27000 cells/cm². Cells were cultured
in BD Falcon™ 8-well CultureSlides (BD Biosciences, Franklin
Lakes, NJ, USA) pre-coated with 0.01% poly-L-lysine (Cultrex,
Trevigen, Gaithersburg, MD, USA) for 2 h at 37°C. For the
transwell assay, Huh-28 and 196hT cell lines were cultured in 12-
well plates containing inserts separated by a polycarbonate
membrane with 0.4 μm pores (Costar, Corning Amsterdam,
Netherlands). Huh-28 or 196hT cells were either plated in the
upper chamber (30,000 cells in 0.5 ml medium) or on 10-mm
round glass coverslips pre-coated with fibronectin (50 μg/ml for
2 h at 37°C) and placed in the lower chamber (100,000 cells in
1.5 ml medium). Huh-28 or 196hT were cultured in the lower
chamber either alone (with only medium in the upper chamber)Frontiers in Immunology | www.frontiersin.org 3or in co-culture (with 196hT or Huh-28, respectively, in the
upper chamber). Cells were cultured in a-MEM plus 10% FBS.
Only the cells from the lower chamber can be analyzed by
immunofluorescence, thanks to their culture on the pre-coated
glass coverslip. For both co-culture and transwell assays, after 4
days of culture without changing the medium, cells were fixed
with 4% formaldehyde (Electron Microscopy Sciences, Hatfield,
PA, USA) diluted in PBS for 10 min at room temperature,
permeabilized for 5 min with 0.1% Triton X-100 (Sigma-
Aldrich, St. Louis, MO, USA), washed twice with PBS, and
blocked for 15 min with 3% bovine serum albumin (Sigma-
Aldrich) in PBS. Cells were then incubated for 1 h with anti-
tenascin-W (56O) diluted at 1:100. After 3 washes with PBS, cells
were incubated for 1 h in the dark with goat anti-mouse antibody
conjugated to Alexa Fluor® 568 (Thermo Fisher Scientific) diluted
at 1:1000. Finally, cell nuclei were counterstained with DAPI
(Sigma-Aldrich) and slides were mounted with ProLong®
Diamond Antifade Mountant (Life Technologies, Waltham, MA,
USA). Images were acquired with an Axio Imager Z1 microscope
(Zeiss, Oberkochen, Germany).
For siRNA transfection, Huh-28 cells were seeded in 6-well
plates with a density of 600,000 cells/well. The day after, cells
were transfected with 25 pmol/well of different Silencer Select®
SiRNAs (Thermo Fischer Scientific) using Lipofectamine
RNAiMAX Transfection Reagent (Thermo Fisher Scientific)
following manufacturer’s instructions. SiRNA TNW 1
(sc34270), siRNA TNW 2 (sc34271) and siRNA TNW 3
(sc34272) were used to knockdown tenascin-W. SiRNA control
1 (Silencer® Negative Control #1, ref 4390843) and siRNA
control 2 (Silencer® Negative Control #2, ref 4390846) were
used as negative control. Cells were collected 3 days post-
transfection and tenascin-W expression was analyzed by
Western blot as described below.
Conditioned Media Preparation
Huh-28, 196hT and293/hTNWcells were cultured inmediumplus
FBS 10% (RPMI 1640, a-MEM and DMEM, respectively) until
reaching approximately 90% confluency. Then, cells were starved
in their respective medium without FBS and antibiotics for 6 days
(Huh-28 and 196hT cell lines) or 3 days (293/hTNW cell line)
before collecting their conditionedmedium.Finally, cell debriswere
removed by centrifugation and the conditioned medium was
concentrated 15X (for Western blots) or 30X (for mass
spectrometry) via precipitation with 10% trichloroacetic acid,
before being resuspended in 4X sample buffer (0.2M Tris-HCl,
145.56mM SDS, 20% glycerol, bromophenol blue) containing
0.1M DTT.
Western Blotting
For cell lysates, cells were lysed in RIPA buffer (50 mM Tris HCl
pH 7.4, 150 mM NaCl, 0.2% Na-deoxycholate, 25 mM Hepes, 5
mM MgCl2) containing protease inhibitors (Complete Mini,
EDTA-free, Roche Diagnostics). Protein concentration was
determined with a Bradford Assay (BradfordUltra, Expedeon,
San Diego, CA, USA). Cell lysates or conditioned media were
separated on 7% polyacrylamide gel under reducing conditionsFebruary 2021 | Volume 11 | Article 630139
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Scientific). Membranes were then stained with Ponceau S to
control for equal protein loading and blotting efficiency. After
blocking for 1 h at room-temperature with 5% Skim Milk
Powder (Sigma-Aldrich) in PBS-Tween-20 0.1% (PBS-T), Blots
were incubated overnight at 4°C with either anti-tenascin-W
(56O) diluted at 1:1000, or anti-GAPDH (ab9485, Abcam,
Cambridge, UK) diluted at 1:1000, as primary antibodies. After
several washing steps with PBS-T, peroxidase-conjugated anti-
mouse IgG (G21040, Life Technologies) or anti-rabbit IgG
(G21234, Life Technologies) for 1 h at room temperature to
detect anti-tenascin-W or anti-GAPDH, respectively. Signal from
immunoblots was detected by enhanced chemiluminescence using
SuperSignal™ West Dura Extended Duration Substrate (Thermo
Fisher Scientific), and exposed to Super RX films (Fujifilm,
Dielsdorf, Switzerland).
RNA Isolation and Gene Expression
Analysis by qRT-PCR
Total RNA was isolated by using QIAshredder and RNeasy Mini
Kit (QIAGEN, Hilden, Germany/Venlo, Netherlands). RNA was
reverse transcribed into cDNA using the High Capacity cDNA
Reverse Transcription Kit (Life Technologies) with oligo-p(dT)
15 (Roche) instead of the random primers provided in the kit.
Quantitative RT-PCR assay was performed with 50 ng of cDNA
from each cell line, using Platinium SYBR Green qPCR
SuperMix-UDG with ROX (Invitrogen, Life Science, Carlsbad,
CA, USA) on a StepOnePlus™ Real-Time PCR System (Life
Technologies). Relative expression of human tenascin-W was
calculated using the DDCT method, normalizing values to
human TBP (TATA-Box binding protein) within each sample.
Primers for human tenascin-W (forward primer: 5 ’-
ATGCCCTCACAGAAATTGACAG-3’ and reverse primer: 5’-
TCTCTGGTCTCTTGGTCGTC-3’) and for human TBP
(forward primer: 5’-TGCACAGGAGCCAAGAGTGAA-3’ and
reverse primer: 5’-CACATCACAGCTCCCCACCA-3’) were
tested for specificity and efficiency.
Mass Spectrometry
Mass spectroscopy was used to determine the identity of the high
molecular weight band recognized by anti-tenascin-W on
Western blots of Huh-28 cell line. For the samples, 293/hTNW
cell lysate and Huh-28 serum-free conditioned medium were
prepared as described above. To analyze the samples by
spectrometry, 50μl of 30X concentrated serum-free Huh-28
conditioned medium and 250μg of 293/hTNW cell lysate were
separated on a 7% SDS-PAGE gel and stained with InstantBlue™
(Expedeon Inc.) in order to visualize the bands of interest. The
protein bands were excised from the gel, reduced with 10mM
TCEP, alkylated with 20mM iodoacetamide and cleaved with 0.1
μg porcine sequencing grade trypsin (Promega) in 25mM
ammonium bicarbonate (pH 8.0) at 37°C for 16 h. The
extracted peptides were analyzed by capillary liquid
chromatography tandem mass spectrometry with an EASY-
nLC 1000 using the two-column set up (Thermo Scientific).
The peptides were loaded in 0.1% formic acid, 2% acetonitrile inFrontiers in Immunology | www.frontiersin.org 4H2O onto a peptide trap (Acclaim PepMap 100, 75um x 2cm,
C18, 3um, 100Å) at a constant pressure of 800 bar. Then they
were separated at a flow rate of 150 nl/min with a linear gradient
of 2–6% buffer B (0.1% formic acid in acetonitrile) in buffer A
(0.1% formic acid) for 3 min followed by an linear increase from
6–22% for 40 min, 22–28% for 9 min, 28–36% for 8 min, and 36–
80% for 1 min. The column was finally washed for 12 min in 80%
buffer B on a 50μm x 15cm ES801 C18, 2μm, 100Å column
mounted on a DPV ion source (New Objective) connected to a
Orbitrap Fusion (Thermo Scientific).
The data were acquired using 120000 resolution for the
peptide measurements in the Orbitrap and a top T (3 s)
method with HCD fragmentation for each precursor and
fragment measurement in the LTQ. Mascot Distiller 2.5 and
MASCOT 2.5 (Matrix Science, London, UK) searching the
human subset of the UniProt version 2015_01 data base
combined with known contaminants was used to identify the
peptides. The enzyme specificity was set to trypsin allowing for
up to three incomplete cleavage sites. Carbamidomethylation of
cysteine (+57.0245) was set as a fixed modification, oxidation of
methionine (+15.9949 Da) and acetylation of protein N-termini
(+42.0106 Da) were set as variable modifications. Parent ion
mass tolerance was set to 10 ppm and fragment ion mass
tolerance to 0.6 Da. The decoy function in Mascot was used
and the results were validated and the false discovery rate (FDR)
was calculated with the program Scaffold Version 4.4 (Proteome
Software, Portland, USA). The peptide threshold was set to an
FDR of 0.1% and for proteins to 1%.Cell Sorting
Huh-28 and 196hT cell lines were cultured in a-MEM plus 10%
FBS, either alone or together at a ratio of 1:1, with a total density
of 27,000 cells/cm². After 4 days of culture, using the ability of
196hT cells to express GFP, cells from both the co-culture and
the monocultures were sorted with a BD Influx cell sorter (BD
Biosciences) and BD FACS™ Sortware sorter software (Version
1.01.654). The sort was performed with a 100-mm nozzle tip, at a
sheath pressure of 19.0 psi, and a frequency of 28.90 kHz. The
following gates were set: gate 1 was forward scatter FSC-Area
against side scatter SSC-Area, gate 2 was FSC-Width against
FSC-Height, gate 3 was SSC-Width against SSC-Height, and gate
4 was 530/40 (488 nm) against 710/50 (561 nm).RESULTS
In all, 30 tumors from patients with biliary tract cancers ranging
in age from 29–79 years old were processed for histopathological
examination as well as anti-tenascin-C and anti-tenascin-W
immunohistochemistry. The results were compared with
normal liver (all negative for HIV, hepatitis B, and hepatitis
C), non-tumoral liver from a patient with ICC, and tissue from
non-tumoral gallbladders that were removed due to cholecystitis.
The results are summarized in Supplementary Table 1 and
Table 1 and are illustrated in Figures 1–3.February 2021 | Volume 11 | Article 630139
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around blood vessels (vein and artery) in the portal tract of
normal liver tissue (Figure 1A). Conversely, anti-tenascin-W
does not immunostain normal hepatic tissue (Figure 1A).
Similarly, tenascin-C immunoreactivity is seen surrounding
blood vessels in the adventitia of a non-tumoral gallbladder
removed from a patient with cholecystitis, around bundles of
smooth muscle in the muscularis externa, and in the lamina
propria of the mucosa (Figure 1B). Tenascin-W immunoreactivity
is not detected in the non-tumoral gallbladder (Figure 1B) and was
not detected in tissues isolated from 5 of the 6 non-tumoral
gallbladders examined (Table 1). The anti-tenascin-W
immunostaining observed in one non-tumoral gallbladder was
weak (+) and only present in a single focal fibrotic area (Table 1).
The presence of tenascin-C immunoreactivity in all the non-tumoral
tissues examined, and the general absence of tenascin-W
immunoreactivity in adjacent sections, led us to examine a broad
array of normal human tissues with the tenascin-W antibodyFrontiers in Immunology | www.frontiersin.org 5(Supplementary Figure 1). As reported by others studying
tenascin-W in mice (24, 25), the anti-tenascin-W immunostains
extracellular matrix in normal adult human spleen and kidney.
Tenascin-W immunoreactivity is also seen in the female
reproductive system (uterus, uterine tubes and ovaries) as well as in
certain glands (adrenal gland, pituitary gland, thyroid and prostate).
Tenascin-W immunoreactivity is not seen in heart, lung or central
nervous system samples, and it is absent or weak in tissues from the
gastrointestinal system (esophagus, stomach, pancreas or colon).
Consistent with our findings (Figure 1A), tenascin-W
immunoreactivity is absent from three additional normal liver
samples that were part of the array.
There is strong anti-tenascin-C immunoreactivity around
sinusoids in the non-tumoral region of a liver sample taken
from a patient with ICC (Figure 2A). As in the non-tumoral
liver, there is no tenascin-W immunoreactivity in this sample.
However, both antibodies immunostain the stroma surrounding
the ICC itself (Figure 2B). Both tenascin-C and tenascin-WA
B
FIGURE 1 | Anti-tenascin-C (TNC) and anti-tenascin-W (TNW) immunohistochemistry of hepatobiliary tissues. (A) TNC immunostaining is observed around sinusoids
(arrowheads) and around a vein (v) and an artery (arrow) in portal tract sections of a normal adult liver. An adjacent section is not labeled with TNW immunohistochemistry
(400X). (B) TNC immunohistochemistry of a non-tumoral adult gallbladder (cholecystitis) shows labeling around vessels in the adventitia (ad), as well as around bundles of
smooth muscle in the muscularis layer (ms). There is also patchy immunoreactivity in the mucosa (mc). In contrast, TNW does not immunolabel gallbladder tissue (40X). A third
section in each series was stained with hematoxylin and eosin (H&E).TABLE 1 | Summary of tenascin immunostaining of normal liver, non-tumoral gallbladder, and hepatobiliary cancers.
Tissue Anti-TNC Anti-TNW*
- + ++ +++ - + ++ +++
Liver (n = 13)** 0/13 5/13 7/13 1/13 13/13 0/13 0/13 0/13
Gallbladder (n = 6)† 0/6 1/6 2/6 3/6 5/6 1/6¶ 0/6 0/6
ICC (n = 8)‡ 0/8 0/8 0/8 8/8 0/8 1/8 2/8 5/8
CPHBD (n = 7)§ 0/7 0/7 1/7 6/7 0/7 2/7 2/7 3/7
CGB (n = 11)‖ 0/11 0/11 0/11 11/11 0/11 1/11 3/11 7/11
CGB liver metastasis (n = 4) 0/4 0/4 0/4 4/4 0/4 0/4 2/4 2/4February 2021 | Volume 11 | Article 63*Intensity of anti-tenascin-C (TNC) and anti-tenascin-W (TNW) immunostaining: -, absent; +, weak; ++, moderate; +++, high.
**Histologically normal liver, negative for HIV, hepatitis B, and hepatitis C.
†From cholecystectomy due to cholecystitis.
‡Intrahepatic cholangiocarcinoma.
§Carcinoma of perihilar bile ducts.
‖Carcinoma of the gallbladder.
¶Focal positivity.0139
Hendaoui et al. Tenascin-W in Biliary Tract Cancersantibodies labeled the stroma of each ICC (n = 8) and CPHBD
(n = 7) examined (Figure 2 and Supplementary Table 1). The
intensity of the anti-tenascin-W immunoreactivity in ICC and
CPHBD is variable, but no clear correlations could be made
between the intensity of the immunostaining and the tumor
grade (Supplementary Table 1). While most of the ICC and
CPHBD examined were well or moderately differentiated
adenocarcinomas (n = 13), the tenascin-W antibody also
immunolabeled the stroma of a single squamous cell carcinoma
(Supplementary Table 1) and a single adenosquamous carcinoma
(Figure 2D).Frontiers in Immunology | www.frontiersin.org 6In all, 11 cases of CGB, as well as 4 independent CGB
metastases to liver, were examined with immunohistochemistry
(Figure 3 and Supplementary Table 1). Anti-tenascin-C and
anti-tenascin-W both immunolabel the stroma of poorly (n = 3),
moderately (n = 4) and well differentiated adenocarcinomas (n =
2), as well as the stroma of a single squamous cell carcinoma
(Figure 3D) and a single mucinous carcinoma (Figure 3E).
There is also tenascin-C and tenascin-W immunoreactivity in
the stroma of CGB hepatic metastases (Figure 3F). As with the
ICC and CPHBD immunostaining, anti-tenascin-W






FIGURE 2 | Adjacent sections through needle biopsies of non-tumoral liver and various intrahepatic cholangiocarcinomas and carcinomas of perihilar bile ducts
immunostained with anti-tenascin-C (TNC) and anti-tenascin-W (TNW). (A) Non-tumoral liver (patient ID 5) is immunostained with TNC, but not TNW (200X).
(B–D) Immunohistochemical examination of intrahepatic cholangiocarcinomas (ICC). Both TNC and TNW label the stroma of a moderately differentiated
adenocarcinoma (B) strongly (patient ID 5; 200X). Antibodies to both tenascin-C and tenascin-W label the stroma of a well differentiated adenocarcinoma (Patient ID
1; C; 100X) and an adenosquamous carcinoma (Patient ID 8; D; 100X). (E, F) Immunolabeling of carcinomas of perihilar bile ducts (CPHBD) with TNC and TNW. The
stroma of a moderately differentiated adenocarcinoma (Patient ID 11; E; 100X) and a well differentiated adenocarcinoma (Patient ID 13; F; 100X) show expression of
both tenascin-C and tenascin-W. A third section in each series was stained with hematoxylin and eosin (H&E).February 2021 | Volume 11 | Article 630139
Hendaoui et al. Tenascin-W in Biliary Tract Cancersintensities, but no clear correlations could be made with the
intensity of the immunostaining and the tumor grade (Table 1).
To maximize anti-tenascin immunostaining, the ICC,
CPHBD and CGB samples shown here were processed using
cryopreservation and sectioning. However, following antigen
retrieval it was also possible to use the antibodies to
immunostain formalin-fixed and paraffin-embedded samples of
CPHBD, ICC and CGB (Supplementary Figure 2).
To determine the potential cellular origins of tenascin-W in
biliary tract cancers and to facilitate future studies of the role of
tenascin-W in these cancers, 20 different human biliary tract cell
lines were examined for tenascin-W RNA expression by qRT-Frontiers in Immunology | www.frontiersin.org 7PCR. While many of the cell lines had low to negligible levels of
expression, ICC-derived Huh-28 cells expressed significant levels
of tenascin-W (Figure 4A). This was confirmed by western
blotting of Huh-28 cell lysates and 15X concentrated Huh-28
cell conditioned medium (Supplementary Figure 3), and by
western blotting of lysates of Huh-28 cells before and after
transfection with tenascin-W-specific siRNAs (Supplementary
Figure 4) and by mass spectrometry (Supplementary Figure 5).
Immunocytochemistry with the anti-tenascin-W shows bright
intracellular staining of cultured Huh-28 cells, but no tenascin-
W-positive fibrils were observed around cells. This leads us to






FIGURE 3 | Sections through needle biopsies of carcinomas of the gallbladder and a hepatic metastasis from a carcinoma of the gallbladder stained with
hematoxylin or immunostained with anti-tenascin-C (TNC) or anti-tenascin-W (TNW). (A–E) Immunostaining of carcinomas of the gallbladder (CGB). The stroma of a
poorly differentiated adenocarcinoma (Patient ID 18; A), a moderately differentiated adenocarcinoma (Patient ID 17; B) and a well differentiated adenocarcinoma
(Patient ID 26; C) are immunolabeled with both TNC and TNW (100X). Both TNC and TNW label the stroma of a squamous carcinoma (Patient ID 19; D; 100X) and
a mucinous carcinoma (Patient ID 22; E; 100X). (F) A representative section through a needle biopsy of a hepatic metastasis from a carcinoma of the gallbladder
(Patient ID 27) shows strong TNC and TNW immunolabeling in the tumor stroma (100X). A third section in each series was stained with hematoxylin and eosin (H&E).February 2021 | Volume 11 | Article 630139
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the extracellular matrix, as observed in the tumor stroma of ICC,
CPHBD and CGB patients (Figure 4B). Since bone marrow-
derived stromal cells (BMSCs) represent a significant cellular
source of cancer-associated fibroblasts that support tumor cell
growth (35), we decided to perform co-culture between Huh-28
and the BMSC cell line 196hT in order to mimic a tumor stroma
microenvironment. While 196hT cells do not express tenascin-
W when cultured alone (Figures 4A, B), the tenascin-W labeled
by immunocytochemistry in co-cultures of Huh-28 with 196hT
cells is organized in fibrils surrounding nests of Huh-28 cells,
mimicking the appearance of tenascin-W in the stroma
surrounding nests of tumor cells in ICC. Similar results were
observed with co-cultures of 196hT cells and other biliary tractFrontiers in Immunology | www.frontiersin.org 8cancer cell lines that express lower levels of tenascin-W: the
CPHBD cell line TFK-1 and the CGB cell line G-415 (not
shown). Since the 196hT cells were genetically engineered to
express GFP (36), it was possible to sort the cells after co-culture
and examine cell-type specific lysates for the expression of
tenascin-W by western blotting (Figure 4C). Huh-28 cell
lysates following co-culture had readily detectable tenascin-W,
but 196hT cells did not (Figure 4D, Supplementary Figure 6),
indicating that the source of the tenascin-W fibrils seen in the co-
cultures is the Huh-28 cells and not the 196hT cells. To
determine if physical contact between the cells or a secreted
factor leads to the appearance of the fibrillar anti-tenascin-W
immunostaining in the co-cultures, the two cells types were




FIGURE 4 | Expression of tenascin-W by cell lines derived from biliary tract tumors. (A) Twenty cell lines were analyzed for tenascin-W expression using qRT-PCR.
The results were plotted as expression relative to that of the housekeeping gene hTBP. Four cells lines were derived from intrahepatic cholangiocarcinomas (ICC),
6 were from carcinoma of perihilar bile ducts (CPHBD), and 10 were from carcinoma of the gallbladder (CGB). For comparison, qRT-PCR expression of tenascin-W
by a bone marrow stromal cell-derived cell line (196hT) is shown. The highest level of tenascin-W expression was seen in the ICC-derived cell line Huh-28;
(B) Immunocytochemistry with anti-tenascin-W (TNW) reveals intracellular labeling of Huh-28 cells, but not 196hT cells. The 196hT cells, but not the Huh-28 cells,
express GFP. The merged images include a DAPI nuclear counterstain. When the two cell lines are co-cultured, tenascin-W-positive fibrils surround nests of Huh-28 cells,
mimicking the arrangement of tenascin-W in the stroma of ICCs. Scale bars = 50 mm. (C) The method used for separating Huh-28 cells from GFP-positive 196hT cells
following co-culture is shown schematically. Illustration was created using Servier Medical Art Powerpoint Image Bank (Servier, https://smart.servier.com/). (D) Tenascin-W can
be detected by immunoblotting with 30µg of cell lysates of Huh-28 cells and Huh-28 cells following co-culture with 196hT cells. Tenascin-W is not detectable in the lysates of
196hT cells or 196hT cells following co-culture. Ponceau S was used as a loading control.February 2021 | Volume 11 | Article 630139
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that allows the diffusion of soluble factors, but not the
transmigration of cells. If 196hT cells are in the upper
chamber, tenascin-W-positive fibrils are seen around Huh-28
cells in the lower chamber, in addition to the tenascin-W
cytoplasmic local izat ion observed in Huh-28 cel ls
(Supplementary Figure 7). If Huh-28 cells are in the upper
chamber, tenascin-W-positive fibrils are seen in 196hT cells in
the lower chamber. However, no tenascin-W immunostaining is
detected in the cytoplasm of 196hT cells. Therefore, soluble
tenascin-W secreted by Huh-28 cells in the upper chamber
becomes associated with fibrils when it enters into contact in
the lower chamber with a soluble factor secreted by 196hT cells.
These results suggest that a secreted factor in the tumor
microenvironment, mimicked by co-cultures of Huh-28 and
196hT cells in vitro, is required for the production and
assembly of tenascin-W-positive fibrils in the tumor stroma,
and that the cancer cells themselves can be/are the source of
tenascin-W, at least in ICC.DISCUSSION
In the current study, tenascin-C immunoreactivity was observed
in the stroma of all biliary tract tumors examined. Its presence in
ICC is consistent with the reports of others who studied animal
models (33) and intrahepatic tumors of biliary origin in humans
(37–39). Antibodies to tenascin-C have been used as an ICC
stromal marker in at least one animal study (40), and in an
effort to identify combinations of antibodies that could
be used for prognosis, a combination of high levels of
tenascin-C immunoreactivity and low levels of osteopontin
immunostaining was found to correlate with low post-surgery
survival rates in patients with ICC (41). Our study appears to be
the first to report tenascin-C immunoreactivity in the stroma of
CPHBD and CGB, though one report has described elevated
levels of tenascin-C in the serum of a patient with metastatic
CGB (42). Thus, CPHBD and CGB can be added to the growing
list of solid tumors in which tenascin-C expression has been well
documented (14–17). Here, we report anti-tenascin-C
immunostaining in normal liver around sinusoids, but also
around veins and arteries in the portal tract, as was shown
previously (43–45).
Tenascin-C exists in multiple isoforms, and different isoforms
are found in different tumors (12). While this complicates the
characterization of tenascin-C in tumor stroma, it has led to the
development of prospective isoform-specific tumor therapies
(12). The monoclonal antibody to tenascin-C used in this
study (B28-13) recognizes an epitope common to all tenascin-
C isoforms (19, 31). Less is known about the possible isoforms of
tenascin-W, but to date immunoblots indicate that only a single
form is expressed in human tumors (19, 29). Interestingly, the
tenascin-W made by the ICC-derived cell line Huh-28 runs
on SDS-PAGE with a higher apparent molecular weight
than expected (Supplementary Figure 4). While this may
be the result of multimerization, it may also represent aFrontiers in Immunology | www.frontiersin.org 9tumor-specific form or modification of the protein. To
unambiguously identify the higher molecular weight band as
tenascin-W we analyzed the tryptic peptides from this region by
tandem mass spectrometry and compared them to the lower
molecular weight band of tenascin-W derived from 293/hTNW
cells (Supplementary Figure 5). Seven tenascin-W peptides
could be identified with good MASCOT scores and a false
discovery rate of 0.1%. They were manually evaluated and had
similar retention times to the peptides derived from 293/hTNW
cells. They are distributed over a wide range of the tenascin-
W sequence.
The anti-tenascin-W used in the current study also
immunostained the stroma of all the biliary tract tumors
examined. However, in contrast to anti-tenascin-C, anti-
tenascin-W did not immunostain normal liver, non-tumoral
liver from 3 patients with ICC, or tissues from 5 of the 6
gallbladders removed from patients with cholecystitis. This
makes tenascin-W a potential candidate for identifying stromal
areas associated with biliary tract tumors and a potential target
for biotherapies. Similar conclusions were drawn by others who
found that tenascin-W immunoreactivity was associated with
glioblastomas, astrocytomas and oligodendrogliomas, but was
absent from normal brain tissue (29). Tenascin-W is also found
in colorectal cancer, but not in normal colon tissue (28). For a
more comprehensive view of tenascin-W expression in normal
human tissues, we surveyed additional normal adult human
tissues using anti-tenascin-W-based immunohistochemistry
and found that many, but not all, lacked tenascin-W
expression. Some normal glands (e.g., prostate) and the female
reproductive system (e.g., the uterus and ovaries) displayed high
levels of tenascin-W expression. This would need to be
considered when developing systemic therapies or using
tenascin-W as a potential marker of tumor stroma in these
regions. Tenascin-W is elevated in the serum of patients with
breast and colorectal cancer (28). It would be interesting to see if
tenascin-W is a potential serum marker for biliary tract cancers
as well, as reliable serum markers for these cancers have yet to be
developed (46).
What is the origin of the tenascin-W found in the stroma of
biliary tract tumors? We were unable to perform in situ
hybridization with probes for tenascin-W transcripts on the
tumor samples, as the fixation protocol was optimized for
immunohistochemistry. However, the expression of tenascin-
W in cell lines derived from ICC (Huh-28), CGB (TGCB2) and
CPHBD (SNU245) is evidence that the cancer cells themselves
may express some of the tenascin-W found in the tumor stroma
(Figure 4A). However, our results do not rule out possible
origins from cancer associated fibroblasts or endothelial cells.
Futures studies should address this question.
Most in vitro studies of tenascin-W expression have involved
primary cultures of embryonic osteoblasts as few cell lines have
been identified that express tenascin-W (47, 48). Here, we found
that tenascin-W transcripts are relatively high in Huh-28 cells,
and tenascin-W can be detected in cell lysates and conditioned
medium of Huh-28 cells (Supplementary Figure 3). Thus, Huh-
28 cells are the first cell line identified that express tenascin-WFebruary 2021 | Volume 11 | Article 630139
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in future studies to elucidate tenascin-W function. The Huh-28
cell line was derived from an ICC removed with the left lobe of
the liver from a 37-year-old woman in 1984 (49). They are large,
spindle-shaped or polygonal cells that proliferate slowly under
typical culture conditions and fail to form tumors when injected
into nude mice (49). A future study could involve co-injection of
BMSCs with the Huh-28 cells to see if this results in tumor
formation. Because they share properties with primary cultures
of cholangiocarcinoma cells, Huh-28 cells have also been used as
an in vitro model for studying the regulation of ICC
proliferation. Like primary ICC cells, Huh-28 cells express
estrogen receptors and their serum-induced proliferation is
inhibited with tamoxifen (50). They also proliferate in response
to IGF-1 (50) and TGF-beta (51). Huh-28 cells also express
relatively high levels of miR-24, a small non-coding RNA
associated with oncogenesis (52). When co-cultured with
immortalized BMSCs, we show here that Huh-28 cells form
nests that are surrounded by fibrils that are immunostained with
anti-tenascin-W, mimicking the arrangement of ICC cells
surrounded by tenascin-W stroma in situ. This may prove to
be a good model for future studies of ICC growth and the
development of anti-ICC therapies. It is also important to note
that as we were unable to acquire phase contrast images of the
co-cultured cells, it is difficult to determine if the tenascin-W-
positive fibrils were on the cell surface or were part of a broader
fibrillar system. Future studies should also be directed at studying
the effects of exogenous tenascin-W on Huh-28 cell proliferation
and behavior, as was done with breast cancer cell lines (21).
The C-terminal fibrinogen-related domain of tenascin-W,
like that of tenascin-C, can activate Toll-like receptor 4-
mediated inflammatory responses (53). Moreover, tenascin-C
was recently shown to contribute to immune suppression in an
oral squamous cell carcinoma model (18). Future studies should
be directed to determine if tenascin-W, which shares a number of
features with tenascin-C, plays a similar role in tumor stroma, or
if the presence of tenascin-W during cholelithiasis could
contribute to tumor progression.
The extracellular matrix glycoprotein tenascin-W is found in
the stroma of ICC, CPHBD and CGB. It is not expressed in
normal liver or most cholecystitic gallbladders. Thus, tenascin-W
is potentially a novel stromal marker for biliary tract cancers and
may prove useful in the development of biotherapies.DATA AVAILABILITY STATEMENT
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(Institute of Pathology, University Hospital of Basel, Basel,
Switzerland) for technical help with FFPE sections. We thank
Mounira Ben Mustapha and Khadija Ben Hmida-Saad
(Mongi Slim University Hospital, La Marsa, Tunisia) for
administrative assistance.SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online
at: https://www.frontiersin.org/articles/10.3389/fimmu.2020.
630139/full#supplementary-materialFebruary 2021 | Volume 11 | Article 630139
Hendaoui et al. Tenascin-W in Biliary Tract CancersREFERENCES
1. Mertens JC, Rizvi S, Gores GJ. Targeting cholangiocarcinoma. Biochim
Biophys Acta (2018) 1864:1454–60. doi: 10.1016/j.bbadis.2017.08.027
2. Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. Clin
Epidemiol (2014) 6:99–109. doi: 10.2147/CLEP.S37357
3. Henson DE, Albores-Saavedra J, Corle D. Carcinoma of the gallbladder.
(1992). Histologic types, stage of disease, grade, and survival rates. Cancer
70:1493–7. doi: 10.1002/1097-0142(19920915)70:6<1498::aid-cncr282070
0609>3.0.co;2-c
4. Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide:
geographical distribution and risk factors. Int J Cancer (2006) 118:1591–
602. doi: 10.1002/ijc.21683
5. Konstantinidis IT, Deshpande V, Genevay M, Berger D, Fernandez-del
Castillo C, Tanabe KK, et al. Trends in presentation and survival for
gallbladder cancer during a period of more than 4 decades: a single-
institution experience. Arch Surg (2009) 144:441–7. doi: 10.1001/
archsurg.2009.46
6. de Aretxabala X, Riedeman P, Burgos L, Roa I, Araya JC, Echeverrıá X, et al.
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